Chronic Myeloid Leukemia: Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

In the eight major markets (8MM), the diagnosed incident cases of CML are expected to increase from 15,515 cases in 2020, at an Annual Growth Rate (AGR) of more than 1%. In 2030, the US will have the highest number of diagnosed incident cases of CML in the 8MM, whereas Canada will have the fewest diagnosed incident cases. In the 8MM, the 20-year diagnosed prevalent cases of CML are expected to increase from 142,404 cases in 2020 at an AGR of more than 1.5%. GlobalData epidemiologists attribute the increase in the diagnosed incident cases and 20-year diagnosed prevalent cases of CML to population dynamics, as well as changes in the diagnosed incidence and survival rates in each market.

The diagnosed incidence of CML in men in the 8MM will increase minimally during 2010-2030. In 2020, Canada had the highest diagnosed incidence of CML in men with 2.67 cases per 100,000 population, followed by the US with 2.65 cases per 100,000 population and Japan with 2.28 cases per 100,000 population. In 2020, the UK had the lowest diagnosed incidence of CML in men with 1.39 cases per 100,000 population. The diagnosed incidence of CML in women in the 8MM will increase minimally during 2010-2030 similar to that observed for the incidence trends in men. In 2020, the US had the highest diagnosed incidence of CML in women, followed by Canada and Spain. In 2020, France had the lowest diagnosed incidence of CML in women. This report provides an overview of the risk factors, comorbidities, and the global and historical trends for CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).

What are the diagnosed incident cases of CML by staging?

In 2020, for the 8MM combined, the chronic phase accounted for the majority of the diagnosed incident cases of CML, with more than 90%, followed by the accelerated phase. The blast phase accounted for the fewest number of diagnosed incident cases of CML in the 8MM. This distribution was observed in all the markets.

Diagnosed incident cases of CML by staging

Diagnosed incident cases of CML by staging

For more insights, download a free report sample

What are the diagnosed incident cases of CML by risk status?

In 2020, for the 8MM combined, low-risk accounted for the majority of the diagnosed incident cases of CML, followed by intermediate-risk. High-risk accounted for the fewest number of diagnosed incident cases of CML in the 8MM with more than 20% cases. This distribution was similar in all the markets, except Italy, where intermediate-risk cases were marginally higher than low-risk cases.

Diagnosed incident cases of CML by risk status

Diagnosed incident cases of CML by risk status

For more insights, download a free report sample

What are the diagnosed incident cases of CML in the 8MM?

The 8MM include the US, Canada, France, Germany, Italy, Spain, the UK, and Japan. In 2020, the US accounted for more than 45% of the diagnosed incident cases of CML among the 8MM, with 7,433 cases. There were 4,988 cases in the 5EU in 2020, of the diagnosed incident cases, while Japan had more than 12% cases and Canada had more than 5% cases. In the 8MM, the number of diagnosed incident cases of CML will grow by more than 10% over the forecast period at an Annual Growth Rate (AGR) of more than 1% by 2030. Of the 8MM, Canada is expected to have the highest AGR of more than 2% with the diagnosed incident cases increasing by 2030. Canada will have the lowest number of diagnosed incident cases of CML in 2030. Any change in the diagnosed incident cases of CML is attributable to changing population demographics and changing diagnosed incident rates based on trend analysis in the 8MM.

Diagnosed incident cases of CML in the 8MM, by country

Diagnosed incident cases of CML in the 8MM, by country

For more regional insights, download a free report sample

Market report scope

Key stages Chronic Phase, Accelerated Phase, and Blast Phase
Risk Status Low-Risk, Intermediate-Risk, and High Risk
Key Countries The US, France, Germany, Italy, Spain, UK, Japan, and Canada

Scope

This report provides an in-depth analysis of the following:

  • The Chronic Myeloid Leukemia (CML) Epidemiology Report and Model provide an overview of the risk factors and global trends of CML in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CML. The diagnosed incident cases are segmented by age (all ages), sex, staging (chronic phase, accelerated phase, and blast phase), risk status (low-risk, intermediate-risk, and high-risk), and T315I mutation. The report also provides a 10-year epidemiological forecast of the 20-year diagnosed prevalent cases of CML. The model associated with this report additionally provides diagnosed incident cases of CML segmented by blast phase-lymphoid and blast phase-myeloid leukemia, as well as five-, 10-, and 15-year diagnosed prevalent cases of CML.
  • The CML epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Chronic Myeloid Leukemia (CML) Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global CML market.
  • Quantify patient populations in the global CML market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CML therapeutics in each of the markets covered.
  • Understand the magnitude of the CML population by subtype, digital vasculopathy, and other internal organ involvement.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Chronic Myeloid Leukemia: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Diagnosed Incident Cases of CML

2.4.4 Diagnosed Incident Cases of CML by Staging

2.4.5 Diagnosed Incident Cases of CML by Risk Status

2.4.6 Diagnosed Incident Cases of CML by T315I Mutation

2.4.7 Five-, 10-, 15-, 20-Year Diagnosed Prevalent Cases of CML

2.5 Epidemiological Forecast for CML (2020–2030)

2.5.1 Diagnosed Incident Cases of CML

2.5.2 Age-Specific Diagnosed Incident Cases of CML

2.5.3 Sex-Specific Diagnosed Incident Cases of CML

2.5.4 Diagnosed Incident Cases of CML by Staging

2.5.5 Diagnosed Incident Cases of CML by Risk Status

2.5.6 Diagnosed Incident Cases of CML by T315I Mutation

2.5.7 20-Year Diagnosed Prevalent Cases of CML

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with CML

Figures

Figure 1: 8MM, Diagnosed Incident Cases of CML, Both Sexes, N, All Ages, 2020 and 2030

Figure 2: 8MM, 20-Year Diagnosed Prevalent Cases of CML, Both Sexes, N, All Ages, 2020 and 2030

Figure 3: 8MM, Diagnosed Incidence of CML, Men, Cases Per 100,000 Population, All Ages, 2010–2030

Figure 4: 8MM, Diagnosed Incidence of CML, Women, Cases Per 100,000 Population, All Ages, 2010–2030

Figure 5: 8MM, Sources Used to Forecast Diagnosed Incident Cases of CML (ICD-10 = C92.1)

Figure 6: 8MM, Sources Used to Forecast the Five-, 10-, 15-, and 20-Year Diagnosed Prevalent Cases of CML (ICD-10 = C92.1)

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by Staging

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by Risk Status

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CML (ICD-10 = C92.1) by T315I Mutation

Figure 10: 8MM, Diagnosed Incident Cases of CML, N, Both Sexes, All Ages, 2020

Figure 11: 8MM, Diagnosed Incident Cases of CML by Age, N, All Ages, 2020

Figure 12: 8MM, Diagnosed Incident Cases of CML by Sex, N, All Ages, 2020

Figure 13: 8MM, Diagnosed Prevalent Cases of CML by Staging, N, All Ages, 2020

Figure 14: 8MM, Diagnosed Incident Cases of CML by Risk Status, N, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases of CML by T315I Mutation, N, Both Sexes, All Ages, 2020

Figure 16: 8MM, 20-Year Diagnosed Prevalent Cases of CML, N, Both Sexes, All Ages, 2020

Frequently asked questions

Chronic Myeloid Leukemia: Epidemiology Forecast to 2030 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Myeloid Leukemia: Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Myeloid Leukemia: Epidemiology Forecast to 2030 in real time.

  • Access a live Chronic Myeloid Leukemia: Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.